Conor Stewart
Research expert covering health & pharmaceuticals in the UK & Europe
Get in touch with us now| Characteristic | Worldwide total | Americas |
|---|---|---|
| BCG | 87% | 87% |
| DTP1 | 89% | 90% |
| DTP3 | 84% | 83% |
| HepB BD | 45% | 65% |
| HepB3 | 84% | 83% |
| Hib3 | 76% | 83% |
| HPV last | 15% | 52% |
| MCV1 | 83% | 84% |
| MCV2 | 74% | 76% |
| PCV3 | 60% | 78% |
| Pol3 | 84% | 82% |
| RCV1 | 68% | 84% |
| Rota last | 51% | 74% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Sources
Release date
October 2023
More information
Region
Worldwide, North America, Central and South America
Survey time period
2022
Supplementary notes
* BCG- Bacillus Calmette-Guérin vaccine
DTP3- third dose of diphtheria and tetanus toxoids and pertussis vaccine
HepB BD- birth dose of hepatitis B vaccine
HepB3- third dose of hepatitis B vaccine
Hib3- third dose of Haemophilus influenzae type b vaccine
MCV1- first dose of measles-containing
vaccine
MCV2- second dose of MCV;
PCV3- 3 doses of pneumococcal conjugate vaccine
Pol3- third dose of polio vaccine
RCV- first dose of rubella-containing
vaccine; Rota last- final dose of rotavirus vaccination series.
BCG coverage based on 156 countries with BCG in the national schedule; coverage for all other vaccines based on 194 countries (global) or all countries in the
specified region.
Citation formats
